We are live on ! Find out more
RLAY icon

Relay Therapeutics

157 hedge funds and large institutions have $2.16B invested in Relay Therapeutics in 2023 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 50 increasing their positions, 50 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more funds holding in top 10

Funds holding in top 10: 25 (+3)

18% more call options, than puts

Call options by funds: $5.12M | Put options by funds: $4.35M

14% more capital invested

Capital invested by funds: $1.9B → $2.16B (+$258M)

2% more ownership

Funds ownership: 105.95%107.95% (+2%)

0% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 50

5% less funds holding

Funds holding: 165157 (-8)

22% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 32

Holders
157
Holders Change
-8
Holders Change %
-4.85%
% of All Funds
2.5%
Holding in Top 10
5
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+150%
% of All Funds
0.08%
New
25
Increased
50
Reduced
50
Closed
32
Calls
$5.12M
Puts
$4.35M
Net Calls
+$769K
Net Calls Change
-$925K

RLAY Hedge Fund Activity: Q1 2023 in Review

157 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Relay Therapeutics (RLAY) for Q1 2023, worth a combined $2.16B — up 14% from $1.9B a quarter earlier.

Sellers outnumbered buyers: 32 funds closed out of RLAY and 25 opened new positions — a net loss of 7 holders — while 50 trimmed existing stakes and 50 added.

The largest buyer was Casdin Capital, adding an estimated $47.8M. The largest seller was Morgan Stanley, cutting an estimated $32.4M.

  • 157 institutional investors held Relay Therapeutics (RLAY) as of Q1 2023, down from 165 in Q4 2022.
  • Funds reported $2.16B of Relay Therapeutics stock for Q1 2023, up 14% quarter-over-quarter.
  • 25 funds opened new Relay Therapeutics positions in Q1 2023 and 32 closed out, a net change of -7 holders.
  • The largest Relay Therapeutics buyer in Q1 2023 was Casdin Capital, an estimated $47.8M added.
  • The largest Relay Therapeutics seller in Q1 2023 was Morgan Stanley, an estimated $32.4M sold.

Based on aggregated 13F filings for Q1 2023.